Merus NV 8-K filings

Genmab A/S has completed its acquisition of Merus N.V. for $97.00 per share, leading to the delisting of Merus's common shares from Nasdaq.

Genmab A/S has completed its acquisition of Merus N.V. for approximately $6.9 billion, with 94.2% of shares tendered and significant board and executive leadership changes.

Merus N.V. shareholders overwhelmingly approved all proposals related to the Genmab A/S acquisition, including the $97.00 per share cash offer and director appointments.

Genmab A/S announced its intent to acquire Merus N.V. for $97.00 per share in an all-cash transaction, valued at approximately $8.0 billion, to expand its late-stage oncology pipeline.

Merus N.V. has entered into an underwriting agreement for a public offering of 5,263,158 common shares, with an option for additional shares, aiming to raise approximately $281.7 million in net proceeds to advance its clinical pipeline and fund operations into 2028.

Merus N.V. announced positive interim clinical data from its ongoing Phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab, showing high response rates and promising survival outcomes.

Merus N.V. successfully held its annual general meeting on May 21, 2025, with shareholders approving the adoption of annual accounts, appointment of auditors, director re-appointments, and other key proposals.

Merus N.V. announced that the FDA has approved BIZENGRI for the treatment of certain advanced pancreatic adenocarcinoma and non-small cell lung cancer patients with NRG1 gene fusions.

Merus N.V. has granted Partner Therapeutics exclusive rights to develop and commercialize zenocutuzumab for NRG1+ cancer in the US, with potential for significant milestone payments and royalties.

The FDA has extended the review period for Merus N.V.'s biologics license application for zenocutuzumab to February 4, 2025.

Merus N.V. has appointed Dr. Fabian Zohren as its new Chief Medical Officer, effective July 1, 2024, while also announcing the departures of the current Chief Medical Officer and Chief Business Officer.

Merus N.V. has entered into an underwriting agreement for a public offering of common shares, expected to generate approximately $432.3 million in net proceeds.

Merus N.V. reported promising interim clinical data for its bispecific antibody, petosemtamab, in combination with pembrolizumab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma.

Merus N.V. has filed an amendment to its previous 8-K report to correct a typographical error in the reported abstentions for Proposal 2 at its annual general meeting held on May 7, 2024.

Merus N.V. held its annual general meeting on May 7, 2024, where shareholders approved the extension of the 2016 Incentive Award Plan and re-elected and appointed several non-executive directors.

Merus N.V. has entered into a collaboration and licensing agreement with Gilead Sciences, potentially worth up to $1.5 billion, to develop trispecific antibody products.